Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway

References

• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e34. doi:10.1016/S2214-109X(17)30393-5
   PubMed Web of Science ®Google Scholar
• Gopinath B, Liew G, Burlutsky G, Mitchell P. Age-related macular degeneration and 5-year incidence of impaired activities of daily living. Maturitas. 2014;77(3):263–266. doi:10.1016/j.maturitas.2013.12.001
   PubMed Web of Science ®Google Scholar
• Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97. doi:10.1186/1477-7525-4-97
   PubMed Web of Science ®Google Scholar
• Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606–2617. doi:10.1056/NEJMra0801537
   PubMed Web of Science ®Google Scholar
• Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35(5):1305–1316. doi:10.1038/s41433-020-01377-x
   PubMed Web of Science ®Google Scholar
• Hoeg TB, Ellervik C, Buch H, et al. Danish rural eye study: epidemiology of adult visual impairment. Ophthalmic Epidemiol. 2016;23(1):53–62. doi:10.3109/09286586.2015.1066396
   PubMed Web of Science ®Google Scholar
• Blom K, Bragadottir R, Sivertsen MS, Moe MC, Jorstad OK. Does pharmaceutical compounding of vascular endothelial growth factor inhibitors for intravitreal use alter the risk of post-injection endophthalmitis? Ocul Immunol Inflamm. 2022;30(3):713–716. doi:10.1080/09273948.2020.1820530
   PubMed Web of Science ®Google Scholar
• Berg K, Roald AB, Navaratnam J, Bragadottir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95(8):796–802. doi:10.1111/aos.13522
   PubMed Web of Science ®Google Scholar
• Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PLoS One. 2015;10(6):e0129361. doi:10.1371/journal.pone.0129361
   PubMed Web of Science ®Google Scholar
• Daien V, Finger RP, Talks JS, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105(11):1475–1479. doi:10.1136/bjophthalmol-2020-317434
   PubMed Web of Science ®Google Scholar
• Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725–31 e1. doi:10.1016/j.ajo.2015.06.023
   PubMed Web of Science ®Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234–247. doi:10.1016/j.ophtha.2020.07.060
   PubMed Web of Science ®Google Scholar
• Polat O, Inan S, Ozcan S, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017;47(4):205–210. doi:10.4274/tjo.28003
   PubMedGoogle Scholar
• The Health Research Act. Anonymous human biological material and health data; 2008:20.
   Google Scholar
• Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Br J Ophthalmol. 2010;94(3):319–323. doi:10.1136/bjo.2007.135913
   PubMed Web of Science ®Google Scholar
• Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2003;121(9):1297–1302. doi:10.1001/archopht.121.9.1297
   PubMed Web of Science ®Google Scholar
• Fenwick EK, Xie J, Pesudovs K, et al. Assessing disutility associated with diabetic retinopathy, diabetic macular oedema and associated visual impairment using the vision and quality of life index. Clin Exp Optom. 2012;95(3):362–370. doi:10.1111/j.1444-0938.2012.00742.x
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92(1):89–92. doi:10.1136/bjo.2007.122416
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001;119(5):733–740. doi:10.1001/archopht.119.5.733
   PubMedGoogle Scholar
• Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–946. doi:10.2147/OPTH.S100168
   PubMed Web of Science ®Google Scholar
• Jorstad OK, Steffensen LA, Eriksen K, Bragadottir R, Moe MC. Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway. Acta Ophthalmol. 2020;98(8):774–779. doi:10.1111/aos.14177
   PubMed Web of Science ®Google Scholar
• Kristiansen IS, Haugli Braten R, Jorstad OK, Moe MC, Saether EM. Intravitreal therapy for retinal diseases in Norway 2011–2015. Acta Ophthalmol. 2020;98(3):279–285. doi:10.1111/aos.14262
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19–30. doi:10.1016/j.oret.2019.05.017
   PubMedGoogle Scholar
• Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4(2):122–133. doi:10.1016/j.oret.2019.09.009
   PubMedGoogle Scholar
• Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol. 2022;16:917–933. doi:10.2147/OPTH.S231913
   PubMed Web of Science ®Google Scholar
• Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127–140. doi:10.1080/13548506.2016.1274040
   PubMed Web of Science ®Google Scholar
• Droege KM, Muether PS, Hermann MM, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251(5):1281–1284. doi:10.1007/s00417-012-2177-3
   PubMed Web of Science ®Google Scholar
• Casten RJ, Rovner BW. Update on depression and age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):239–243. doi:10.1097/ICU.0b013e32835f8e55
   PubMed Web of Science ®Google Scholar
• Inger Westborg SA, Jonsson T, Karlsson N, Libert C, Lövestam-Adrian M, Rung L. Årsrapport 2021 - Svenska Makularegistret [Annual report 2021. The Swedish Macula Register]; 2021 Swedish.
   Google Scholar
• Ziemssen F, Feltgen N, Holz FG, et al. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017;17(1):7. doi:10.1186/s12886-017-0401-y
   PubMed Web of Science ®Google Scholar
• Bolme S, Austeng D, Morken TS, Follestad T, Halsteinli V. Cost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norway. BMC Health Serv Res. 2023;23(1):229. doi:10.1186/s12913-023-09186-0
   PubMed Web of Science ®Google Scholar
• Group TE. Vision for change: meeting the growing demand for eye care. Economist Impact; 2022.
   Google Scholar
• Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–146. doi:10.1016/j.preteyeres.2017.12.002
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2(7):645–653. doi:10.1016/j.oret.2018.01.006
   PubMedGoogle Scholar
• Patel P, Sheth V. New and innovative treatments for neovascular age-related macular degeneration (nAMD). J Clin Med. 2021;10:11. doi:10.3390/jcm10112436
   Web of Science ®Google Scholar
• Meer EA, Oh DH, Brodie FL. Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol. 2022;16:4273–4279. doi:10.2147/OPTH.S384995
   PubMed Web of Science ®Google Scholar
• Erke MG, Bertelsen G, Peto T, Sjolie AK, Lindekleiv H, Njolstad I. Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso Eye Study. Ophthalmology. 2012;119(9):1737–1743. doi:10.1016/j.ophtha.2012.03.016
   PubMed Web of Science ®Google Scholar
• Brussaard JH, Brants HA, Bouman M, Lowik MR. The study population: general characteristics and potential confounding factors. Eur J Clin Nutr. 1997;51(Suppl 3):S19–24.
   PubMedGoogle Scholar
• Korkeila K, Suominen S, Ahvenainen J, et al. Non-response and related factors in a nation-wide health survey. Eur J Epidemiol. 2001;17(11):991–999. doi:10.1023/A:1020016922473
   PubMed Web of Science ®Google Scholar
• Sogaard AJ, Selmer R, Bjertness E, Thelle D. The Oslo health study: the impact of self-selection in a large, population-based survey. Int J Equity Health. 2004;3(1):3. doi:10.1186/1475-9276-3-3
   PubMedGoogle Scholar
• Kelfve S, Kivi M, Johansson B, Lindwall M. Going web or staying paper? The use of web-surveys among older people. BMC Med Res Methodol. 2020;20(1):252. doi:10.1186/s12874-020-01138-0
   PubMed Web of Science ®Google Scholar
• Poli A, Kelfve S, Klompstra L, Stromberg A, Jaarsma T, Motel-Klingebiel A. Prediction of (Non)participation of older people in digital health research: exergame intervention study. J Med Internet Res. 2020;22(6):e17884. doi:10.2196/17884
   PubMed Web of Science ®Google Scholar
• Barton J, Bain C, Hennekens CH, et al. Characteristics of respondents and non-respondents to a mailed questionnaire. Am J Public Health. 1980;70(8):823–825. doi:10.2105/AJPH.70.8.823
   PubMed Web of Science ®Google Scholar
• Bostrom G, Hallqvist J, Haglund BJ, Romelsjo A, Svanstrom L, Diderichsen F. Socioeconomic differences in smoking in an urban Swedish population. The bias introduced by non-participation in a mailed questionnaire. Scand J Soc Med. 1993;21(2):77–82. doi:10.1177/140349489302100204
   PubMedGoogle Scholar
• Sonne-Holm S, Sorensen TI, Jensen G, Schnohr P. Influence of fatness, intelligence, education and sociodemographic factors on response rate in a health survey. J Epidemiol Community Health. 1989;43(4):369–374. doi:10.1136/jech.43.4.369
   PubMed Web of Science ®Google Scholar
• van den Akker M, Buntinx F, Metsemakers JF, Knottnerus JA. Morbidity in responders and non-responders in a register-based population survey. Fam Pract. 1998;15(3):261–263. doi:10.1093/fampra/15.3.261
   PubMed Web of Science ®Google Scholar